New clinical trial : in vivo assessment of silver biomaterial nanotoxicity


University of Utah will launch a phase I / phase II clinical trial to assess silver biomaterial nanotoxicity in healthy human volunteers, registered in the Clinicaltrials.gov database under reference NCT01243320. The purpose of the trial is to :

– quantify comprehensive metabolic panel, urinalysis, and CBC with platelet count changes from exposure to 10 ppm silver solution ;

-quantify silver in whole blood and urine by measurement of silver metallic ions (Ag0) ;

-quantify granulocyte and agranulocyte counts, measuring presence of reactive oxygen species (ROS), and determining presence of pro-inflammatory genetic markers from induced sputum ;

-qualify silver nanoparticle retention in human organ systems (on the last day of each phase of the study, all eligible subjects without will undergo a cardiac and abdominal MRI to identify retention Ag0 nanoparticles).

The study is not yet open for participant recruitment.

[[[ Additional links suggested by Nanocolors :

# Silver nanoparticles in biomedical publications since 2000

# Nanomaterials and toxicity in biomedical publications since 2000 ]]]

Advertisements

New clinical trial – Abraxane and carboplatin as first-line treatment for triple negative metastatic breast cancer


Duke University and Abraxis Bioscience recently started a phase II clinical trial involving Abraxane (nanoparticle albumin-bound paclitaxel), now registered in the Clinicaltrials.gov database under reference NCT01207102. The primary objective of the trial is to statistically test whether Abraxane and carboplatin can improve progression-free survival as first-line treatment for “triple negative” (no expression for estrogen, progesterone, or HER2 receptors) metastatic breast cancer. The study is not yet open for participant recruitment.

[[[ Additional links suggested by Nanocolors :

Nanoparticles & cancer therapy : volumetry in biomedical publications since 2000

Nanoparticles in clinical trial trends : comments & focus on Abraxane ]]]

Nano & US university patents : strong Californian leadership, Rice University comes second


This chart was built by searching the Espacenet database for patents

1) mentionning the prefix “nano” in their title or abstract

2) mentionning “univ”, the [US] country code, and the name of the university in the “applicant” field

3) without any restriction of publication year

Only the top 10 most visible US universities according to these criteria are presented in the chart.

University nanotechnology patents : China, USA and Korea most productive countries


This chart was built by searching the Espacenet database for patents

1) mentionning the prefix “nano” in their title or abstract

2) mentionning “univ” and the country code in the “applicant” field

3) without any restriction of publication year

Only the top 10 most visible countries according to these criteria are presented in the chart.

USA risk losing global leadership in nanotech


According to a new report from Lux Research, “In terms of sheer volume, The U.S. dominated the rest of the world in nanotech funding and new patents last year (…). But (…) countries such as China and Russia launched new challenges to U.S. dominance in 2009, while smaller players such as Japan, Germany and South Korea surpassed the United States in terms of commercializing nanotechnology and products.” (press release)

 [[[ Additional links suggested by Nanocolors :

Has China already passed America in nanotechnology?

Nano-related patents – the most visible countries 

Ranking the nations on nanotech ]]]

Gates Foundation funds innovative global health projects including sweat-triggered vaccine delivery using nanoparticles


The Bill & Melinda Gates Foundation announced a few days ago 78 grants of US$100,000 each for new innovative global health projects. Among those aiming at more effective vaccines, one involves nanoparticles : “Sweat-triggered vaccine delivery: Carlos Alberto Guzman of the Helmholtz Centre for Infection Research in Germany with Claus-Michael Lehr and Steffi Hansen of the Helmholtz-Institute for Pharmaceutical Research will develop nanoparticles that penetrate the skin through hair follicles and burst upon contact with human sweat to release vaccines.” (press release)

[[[ Additional link suggested by Nanocolors :

# Nano & vaccines in patents since 2000 ]]]

New clinical trial involving a paclitaxel nanoparticle formulation


With the collaboration of Abbott, a Wake Forest University scientist is conducting a clinical trial to study the best dose and best way to give paricalcitol and to see how well it works when given together with chemotherapy in treating patients with metastatic breast cancer. It is now registered in the ClinicalTrials.gov database under reference NCT01055288. According to this page : “Beginning on day 1, patients receive oral paricalcitol. Patients also receive paclitaxel albumin-stabilized nanoparticle formulation, docetaxel, or paclitaxel once a week or ixabepilone once every 3 weeks. Treatment continues for at least 12 weeks in the absence of disease progression or unacceptable toxicity